Lunai Bioworks (NASDAQ:RENB) Shares Up 12.2% – Still a Buy?

Lunai Bioworks Inc. (NASDAQ:RENB) shares shot up 12.2% during mid-day trading on Tuesday . The company traded as high as $1.43 and last traded at $1.42. 880,400 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 3,746,845 shares. The stock had previously closed at $1.27.

Lunai Bioworks Price Performance

The firm has a market cap of $244.41 million, a PE ratio of -1.84 and a beta of 0.54. The firm has a 50-day simple moving average of $2.22 and a 200 day simple moving average of $3.25.

Institutional Investors Weigh In On Lunai Bioworks

Institutional investors have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in shares of Lunai Bioworks during the second quarter valued at approximately $258,000. Qube Research & Technologies Ltd purchased a new stake in Lunai Bioworks during the 2nd quarter valued at $66,000. Marshall Wace LLP bought a new position in shares of Lunai Bioworks during the 2nd quarter valued at $90,000. Nuveen LLC purchased a new position in shares of Lunai Bioworks in the 1st quarter worth $82,000. Finally, ProShare Advisors LLC bought a new stake in shares of Lunai Bioworks in the fourth quarter worth $27,000. 71.41% of the stock is owned by hedge funds and other institutional investors.

About Lunai Bioworks

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.